EUVIMEDEUVIMED entdecken
Open Access

Preclinical Safety and Toxicological Assessment of Vitamin B 12 Producing Probiotic Limosilactobacillus reuteri NCDC 958

S V Salini, Battula Narsimlu, Angela Joseph, Manorama Kumari, Pradip V Behare iD

Molecular Nutrition & Food Research · 2026-08 · 70 (15)

DOI: 10.1002/mnfr.70546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, online erschienen am 28.07.2026. Verfasst von S V Salini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Techno-functional Starter Lab, National Collection of Dairy Cultures (NCDC), Dairy Microbiology Division, ICAR-NDRI, Karnal, Haryana, India. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, Probiotics, Vitamin B 12. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ICAR-National Dairy Research Institute, National Centre for Veterinary Type Culture Collection (NCVTC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of functional dairy foods using probiotic cultures with additional nutritional benefits has gained considerable attention. Limosilactobacillus reuteri NCDC 958 (LRN958) has been identified as a probiotic strain with the ability to produce vitamin B 12 ; however, establishing its safety profile is essential for its successful application in food and human use. In this study, the preclinical safety of the vitamin B 12 ‐producing LRN958 strain was assessed using integrated in vitro and in vivo approaches. In vitro evaluation revealed that the strain lacked virulence‐associated genes, did not produce biogenic amines or degrade mucin, and was susceptible to recommended antibiotics. In vivo safety was examined through acute, sub‐acute, and sub‐chronic oral toxicity studies in mice. Administration of LRN958 caused no mortality or clinical signs of toxicity. Body weight, hematological and biochemical parameters, organ indices, and histopathology remained comparable to controls. No bacterial translocation was observed, and immune markers, including IgA, IgG, IL‐10, TGF‐β, IL‐6, and TNF‐α, which showed no significant differences, indicating maintained immune homeostasis. The no‐observed‐effect level (NOEL) was 10 10 CFU/mouse/day. Overall, the findings confirm that LRN958 is safe, non‐pathogenic, and supports its potential clinical use and application in probiotic and functional food formulations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Limosilactobacillus reuteriProbioticsVitamin B 12AnimalsMiceFemaleMaleNo-Observed-Adverse-Effect Level

Stichwörter der Autor:innen

Limosilactobacillus reuteripreclinical oral toxicityprobioticssafety evaluationvitamin B12

Substanzen

Vitamin B 12

Autor:innen und Institutionen

  • Techno-functional Starter Lab, National Collection of Dairy Cultures (NCDC), Dairy Microbiology Division, ICAR-NDRI, Karnal, Haryana, India.

ORCID-Profile: Pradip V Behare

Förderung

  • ICAR-National Dairy Research Institute
  • National Centre for Veterinary Type Culture Collection (NCVTC)

Zitieren

APA

Salini, S. V., Narsimlu, B., Joseph, A., Kumari, M., & Behare, P. V. (2026). Preclinical Safety and Toxicological Assessment of Vitamin B 12 Producing Probiotic Limosilactobacillus reuteri NCDC 958. Molecular Nutrition & Food Research, 70(15). https://doi.org/10.1002/mnfr.70546

Vancouver

Salini SV, Narsimlu B, Joseph A, Kumari M, Behare PV. Preclinical Safety and Toxicological Assessment of Vitamin B 12 Producing Probiotic Limosilactobacillus reuteri NCDC 958. Molecular Nutrition & Food Research. 2026;70(15). doi:10.1002/mnfr.70546

BibTeX
@article{Salini2026,
  author = {Salini, S V and Narsimlu, Battula and Joseph, Angela and Kumari, Manorama and Behare, Pradip V},
  title = {Preclinical Safety and Toxicological Assessment of Vitamin B 12 Producing Probiotic Limosilactobacillus reuteri NCDC 958},
  journal = {Molecular Nutrition & Food Research},
  year = {2026},
  volume = {70},
  number = {15},
  doi = {10.1002/mnfr.70546}
}
Kostenlos starten →